l-DOPA Cyclohexyl Ester Is a Novel Potent and Relatively Stable Competitive Antagonist Against l-DOPA Among Several l-DOPA Ester Compounds

Furukawa, Nobuya; Goshima, Yoshio; Miyamae, Takeaki; Sugiyama, Yoshifumi; Shimizu, Minako; Ohshima, Etsuo; Suzuki, Fumio; Arai, Nobutaka; Fujita, Kiyohide; Misu, Yoshimi

doi:10.1254/jjp.82.40

Cited by 30 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, DOPA microinjection into NTS reduced blood pressure and heart rate (Kubo et al, 1992). This response was competitively antagonized by the pretreatment with the microinjection of DOPA ester compounds, DOPAmethylester or DOPA-cyclohexylester (DOPA-CHE), into NTS (Furukawa et al, 2000). Thus, DOPA may act as a neurotransmitter in the central nervous system.…”

Section: Introductionmentioning

confidence: 98%

Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Binding experiments using radiolabelled glutamatergic ligands show that DOPA ME and DOPA CHE, competitive antagonists for DOPA (14), Fig. 1.…”

Section: Dopaergic Relay In the Lower Brainstemmentioning

confidence: 95%

“…Previous studies indicated that DOPA ME and DOPA CHE could act as competitive antagonists against DOPA-induced facilitation of impulseevoked noradrenaline release from rat hypothalamic slices (40) and against DOPA-induced depressor and bradycardic actions in the NTS of anesthetized rats (14). For example, DOPA CHE (30 -100 ng) microinjected in the NTS dose-dependently shifts the dose-responsecurve for l-DOPA (18 -300 ng) to the right, with DOPA CHE (100 ng) inducing a slight reduction of the Typical traces of the effects of DOPA and glutamate (Glu) microinjected into the right or left NTS infected with scramble-(scramble-Ad) or oa1-specific shRNA adenovirus (oa1-Ad) vectors on blood pressure (BP) and heart rate (HR) in anaesthetized rats.…”

Section: Dopa Che Behaves As An Antagonist Of Dopa In Oa1-expressing mentioning

confidence: 99%

“…Modified from (21). maximum response (14 (41). However, this might not reflect the nature of OA1 in native cells because the possibility of a low expression of OA1 or other factors in such cell lines cannot be excluded.…”

Section: Dopa Che Behaves As An Antagonist Of Dopa In Oa1-expressing mentioning

confidence: 99%

“…DOPA produces various presynaptic and postsynaptic responses even under essentially complete inhibition of AADC, and these actions are distinct from those of dopamine (11 -13). The actions of DOPA are antagonized by DOPA methyl ester (DOPA ME) or DOPA cyclohexyl ester (DOPA CHE) in a competitive fashion (7,14). A most prominent effect of DOPA is its depressor and bradycardic actions in the nucleus tractus solitarii (NTS) in anesthetized rats (7,12).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Cardiovascular Actions of DOPA Mediated by the Gene Product of ocular albinism 1

et al. 2014

Self Cite

View full text Add to dashboard Cite

Abstract. l-3,4-Dihydroxyphenylalanine (DOPA) is the metabolic precursor of dopamine, and the single most effective agent in the treatment of Parkinson's disease. One problem with DOPA therapy for Parkinson's disease is its cardiovascular side effects including hypotension and syncope, the underlying mechanisms of which are largely unknown. We proposed that DOPA is a neurotransmitter in the central nervous system, but specific receptors for DOPA had not been identified. Recently, the gene product of ocular albinism 1 (OA1) was shown to possess DOPAbinding activity. It was unknown, however, whether or not OA1 is responsible for the actions of DOPA itself. Immunohistochemical examination revealed that OA1 was expressed in the nucleus tractus solitarii (NTS). OA1-positive cells adjacent to tyrosine hydroxylase-positive cell bodies and nerve fibers were detected in the depressor sites of the NTS. OA1 knockdown using oa1-specific shRNA-adenovirus vectors in the NTS reduced the expression levels of OA1 in the NTS. The prior injection of the shRNA against OA1 suppressed the depressor and bradycardic responses to DOPA but not to glutamate in the NTS of anesthetized rats. Thus OA-1 is a functional receptor of DOPA in the NTS, which warrants reexamination of the mechanisms for the therapeutic and untoward actions of DOPA.

show abstract

Supramolecular Chiral Nanozymes with High and Switchable Enantioselectivity

et al. 2023

View full text Add to dashboard Cite

Understanding and manipulation of catalytic enantioselectivity have emerged as a paramount challenge for decades. Inspired by nature, nanozymes with enantioselectivity have been designed. However, the role of the spatial arrangement interplayed in enantioselective catalysis is rarely paid attention, let alone the manipulation of enantioselectivity switch under this context. Herein, the supramolecular chiral nanozymes composed of P/M‐polyaniline (P/M‐PANI) nanotwists and Fe3O4 nanoparticles without any chiral molecules are constructed. Taking the catalytic oxidation of 3,4‐dihydroxy‐d / l‐phenylalanine (d / l‐DOPA) as a model reaction, P‐PANI–Fe3O4 nanozymes are demonstrated to show better catalytic efficiency toward D‐DOPA, whereas M‐PANI–Fe3O4 nanozymes show preference to L‐DOPA. Intriguingly, through the simple modulation of the Fe3O4 nanoparticle density on P/M‐PANI–Fe3O4, the unprecedented enantioselectivity switch of the as‐designed nanozymes is achieved. Moreover, the select factors of P/M‐PANI–Fe3O4 toward d / l‐DOPA are determined to be significantly larger than that of commonly used chiral ligands (such as d / l‐phenylalanine)‐modified Fe3O4 nanozymes, indicating the superiority of spatial arrangement‐dominated supramolecular chirality over molecular chirality in enantioselectivity. This finding discloses the role that the spatial arrangement‐directed chiral scaffolds interplay in the enzymatic catalytic process and open a new avenue for the facile design of smart nanozymes with controlled enantioselectivity.

show abstract

l-DOPA Cyclohexyl Ester Is a Novel Potent and Relatively Stable Competitive Antagonist Against l-DOPA Among Several l-DOPA Ester Compounds

Cited by 30 publications

References 38 publications

Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs

Expression of ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both neuronal and non-neuronal organs

The Cardiovascular Actions of DOPA Mediated by the Gene Product of ocular albinism 1

Supramolecular Chiral Nanozymes with High and Switchable Enantioselectivity

Contact Info

Product

Resources

About